Urinary Metabolite Markers of Precocious Puberty

Qi, Ying; Пин, Ли; Zhang, Yongyu; Cui, Lulu; Guo, Zhao; Xie, Guoxiang; Su, Mingming; X, Li; Zheng, Xiaojiao; Qiu, Yunping; Liu, Yumin; Zhao, Aihua; Jia, Weiping; Wang, Jia

doi:10.1074/mcp.m111.011072

Cited by 93 publications

(36 citation statements)

References 64 publications

(74 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19,20 In brief, partial least squares-discriminant analysis (PLS-DA) was performed to differentiate distinct bile acid features of all groups. Then orthogonal partial least squares-discriminant analysis (OPLS-DA) was used to identify the differences between BA and NHS.…”

Section: Discussionmentioning

confidence: 99%

Distinct Plasma Bile Acid Profiles of Biliary Atresia and Neonatal Hepatitis Syndrome

et al. 2015

Self Cite

View full text Add to dashboard Cite

Biliary atresia (BA) is a severe chronic cholestasis disorder of infants that leads to death if not treated on time. Neonatal hepatitis syndrome (NHS) is another leading cause of neonatal cholestasis confounding the diagnosis of BA. Recent studies indicate that altered bile acid metabolism is closely associated with liver injury and cholestasis. In this study, we systematically measured the bile acid metabolome in plasma of BA, NHS, and healthy controls. Liver bile acids were also measured using biopsy samples from 48 BA and 16 NHS infants undergoing operative cholangiography as well as 5 normal adjacent nontumor liver tissues taken from hepatoblastoma patients as controls. Both BA and NHS samples had significantly elevated bile acid levels in plasma compared to normal controls. BA patients showed a distinct bile acid profile characterized by the higher taurochenodeoxycholic acid (TCDCA) level and lower chenodeoxycholic acid (CDCA) level than those in NHS patients. The ratio of TCDCA to CDCA in plasma was significantly higher in BA compared to healthy infants (p < 0.001) or NHS (p < 0.001). The area under receiver operating characteristic curve for TCDCA/CDCA to differentiate BA from NHS was 0.923 (95% CI: 0.862-0.984). These findings were supported by significantly altered expression levels of bile acid transporters and nuclear receptors in liver including farnesoid X receptor (FXR), small heterodimer partner (SHP), bile salt export pump (BSEP), and multidrug resistant protein 3 (MDR3) in BA compared to NHS. Taken together, the plasma bile acid profiles are distinct in BA, NHS, and normal infants, as characterized by the ratio of TCDCA/CDCA differentially distributed among the three groups of infants.

show abstract

Section: Discussionmentioning

confidence: 99%

Distinct Plasma Bile Acid Profiles of Biliary Atresia and Neonatal Hepatitis Syndrome

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…A 99-iteration permutation test was performed to rule out non-randomness of separation between groups. The metabolites with variable importance (VIP) values of no less than 1 (equivalent to a p -value of less than 0.5) and a correlation coefficient of |r| > 0.301 (equivalent to a p -value of less than 0.5) were identified as the differential metabolites responsible for sample differentiation3940 and then entered into a multivariate logistic-regression model. A forward selection method was used to obtain a model in which all data had a p -value of less than 0.01.…”

Section: Methodsmentioning

confidence: 99%

Combined Application of NMR- and GC-MS-Based Metabonomics Yields a Superior Urinary Biomarker Panel for Bipolar Disorder

Chen

Liu

Fan

et al. 2014

Sci Rep

View full text Add to dashboard Cite

Bipolar disorder (BD) is a debilitating mental disorder that cannot be diagnosed by objective laboratory-based modalities. Our previous studies have independently used nuclear magnetic resonance (NMR)-based and gas chromatography-mass spectrometry (GC-MS)-based metabonomic methods to characterize the urinary metabolic profiles of BD subjects and healthy controls (HC). However, the combined application of NMR spectroscopy and GC-MS may identify a more comprehensive metabolite panel than any single metabonomic platform alone. Therefore, here we applied a dual platform (NMR spectroscopy and GC-MS) that generated a panel of five metabolite biomarkers for BD-four GC-MS-derived metabolites and one NMR-derived metabolite. This composite biomarker panel could effectively discriminate BD subjects from HC, achieving an area under receiver operating characteristic curve (AUC) values of 0.974 in a training set and 0.964 in a test set. Moreover, the diagnostic performance of this panel was significantly superior to the previous single platform-derived metabolite panels. Thus, the urinary biomarker panel identified here shows promise as an effective diagnostic tool for BD. These findings also demonstrate the complementary nature of NMR spectroscopy and GC-MS for metabonomic analysis, suggesting that the combination of NMR spectroscopy and GC-MS can identify a more comprehensive metabolite panel than applying each platform in isolation.

show abstract

“…However, there are still no objective laboratory tests to help clinicians in the diagnosis of MDD, although many studies have been done to develop these tests 4–6. Our group has conducted many studies for identifying potential biomarkers for MDD diagnosis using metabolomics,7–9 which is used to identify novel biomarkers for various disease states 10–12. Another dilemma about the prevention and treatment of MDD is that no existing antidepressants could treat MDD patients with 100% response rate.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies

Han

Chen

Zou

et al. 2016

NDT

View full text Add to dashboard Cite

BackgroundAn increasing number of studies are reporting that ketamine could be treated as a novel antidepressant for major depressive disorder (MDD). Therefore, we performed this meta-analysis to comprehensively and systematically assess the efficacy of ketamine for treating patients with MDD.MethodRandomized, double-blind, placebo-controlled studies on ketamine versus placebo for treating MDD were searched up to April 2016 in medical databases (PubMed, CCTR, Web of Science, Embase, CBM-disc, and CNKI). Three treatment time points (24 and 72 h, and day 7) were chosen. Response and remission rates were the main outcomes. The random effects model was used. An intention-to-treat analysis was conducted.ResultsNine high-quality studies that included 368 patients were selected to compare the efficacy of ketamine to placebo. The therapeutic effects of ketamine at 24 and 72 h, and day 7 were found to be significantly better than placebo. Response and remission rates in the ketamine group at 24 and 72 h, and day 7 were 52.2% and 20.6%; 47.9% and 23.8%; and 39.8% and 26.2%, respectively. No significant heterogeneity existed, and the Egger’s test showed no publication bias.ConclusionThese results indicated that ketamine could yield a good efficacy in the rapid treatment of MDD. Future large-scale clinical studies are needed to confirm our results and investigate the mid- and long-term efficacy of ketamine in treating MDD.

show abstract

Urinary Metabolite Markers of Precocious Puberty

Cited by 93 publications

References 64 publications

Distinct Plasma Bile Acid Profiles of Biliary Atresia and Neonatal Hepatitis Syndrome

Distinct Plasma Bile Acid Profiles of Biliary Atresia and Neonatal Hepatitis Syndrome

Combined Application of NMR- and GC-MS-Based Metabonomics Yields a Superior Urinary Biomarker Panel for Bipolar Disorder

Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies

Contact Info

Product

Resources

About